Advertisement

Sektion II Praxis

  • E. B. Helm
  • G. Just-Nübling
  • C. Jacobowski
  • H. Knechten
  • A. Goetzenich
  • K. Bröker
  • B. Knupp
  • P. Gute
  • J. Gölz
  • S. Nzimegne-Gölz
Chapter
  • 39 Downloads

Zusammenfassung

Der 60-jährige Patient wurde am 31.12.2002 wegen schwerer, nicht blutiger Durchfälle, Nachtschweiß, Müdigkeit und subfebrilen Temperaturen sowie allgemeiner Abgeschlagenheit und brennenden perianalen Schmerzen aufgenommen.

Literatur

  1. 1.
    Mellors JW, Munoz A, Giorgi JI, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 1997; 126: 946–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351: 543–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Palella FJ, Jr., Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee LM, Karon JM, Selik R, etal.: Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA 2001; 285: 1308–1315.PubMedCrossRefGoogle Scholar
  6. 6.
    Raboud JM, Montaner JS, Conway B, et al.: Suppression of plasma viral load below 20 copies/ml is required to achieve a longterm response to therapy. AIDS 1998; 12: p1619–24.CrossRefGoogle Scholar
  7. 7.
    Kempf DJ, Rode RA, Xu Y, et al.: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9 - F14.PubMedCrossRefGoogle Scholar
  8. 8.
    Hirsch MS, Conway B, D’Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society — USA Panel. JAMA 1998; 279:p 1984–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Arminio Monforte A, Testa L, Adorni F, et al.: Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages ofHIV-1 infection. AIDS 1998; 12: 1631–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Volberding PA, Lagakos SW, Koch MA, et al.: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322: p941–9.CrossRefGoogle Scholar
  11. 11.
    Mulder JW, Cooper DA, Mathiesen L, et al.: Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk ofprogression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017). AIDS 1994; 8: 313–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Volberding PA, Lagakos SW, Grimes JM, et al.: A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med 1995; 333: 401–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994; 343: 871–81.CrossRefGoogle Scholar
  14. 14.
    Kinloch-De Loes S, Hirschei BJ, Hoen B, et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Lindbäck S, Vizzard J, Cooper DA, Gaines H: Long-term prognosis following Zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. JID 1999; 179: 1549–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Murphy RL, Brun S, Hicks C, et al.: ABT378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS, 2001. 15: p. F1–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Rockstroh JK, Bergmann P Wesel W Rieke A, Thiesen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H.: Efficacy and safety of twice daily first-line ritonavir/ indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group. AIDS 2000; 14 (9): 1181–5PubMedCrossRefGoogle Scholar
  18. 18.
    Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865–1873PubMedCrossRefGoogle Scholar
  19. 19.
    Staszewski S, Keiser P, Gathe J, etal.: Comparison of antiviral response with abacavir/ combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CNA3005). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 1999. (Abstract 505).Google Scholar
  20. 20.
    Ruane P Parenti D, Hessenthaler S, Shepp D, Spragion D, Kauf T, Yau L, St. Clair M, Goodwin D, Hernandez J for the COL30336 Study Team: The PI-sparing, compact, quad regimen of Combivir/Abacavir/efavirenz (AOM/ABC/EFV) is potent and well tolerated in naive subjects with high viral loads: 24-week data. 1st IAS Conference on HIV Pathogenesis and Treatment, BuenosAires, Argentina, July 8–11, 2001, Abstract # 221.Google Scholar
  21. 21.
    Back DJ, Gibbons SE, Khoo SH, Merry C, Barry MG, Mulcahy FM., Therapeutic drug monitoring of antiretrovirals: ready for the clinic? J Int Assoc Physicians AIDS Care 2000; 6: 34–7.Google Scholar
  22. 22.
    Piscitelli S, Bechtel C, Sadler B, Falloon J., The addition of a second protease inhibitor eliminated amprenavir-efavirenz interactions and increased amprenavir concentrations. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000. (Abstract 90).Google Scholar
  23. 23.
    Saah AJ, Wìnchell G, SeniukM, Deutsch P Multiple-dose pharmacokinetics and tolerability of indinavir-ritonavir combinations in healthy volunteers. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, 1999. (Abstract 136).Google Scholar
  24. 24.
    Cameron DW, Japour AJ, Xu Y, et al.: Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS, 1999. 13: p. 213–224.PubMedCrossRefGoogle Scholar
  25. 25.
    Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731–1734.PubMedCrossRefGoogle Scholar
  26. 26.
    D’Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401–408.PubMedCrossRefGoogle Scholar
  27. 27.
    DeGruttola V, Dix L, A ‘Aquila R, et al.: The relationship between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5: 43–50.Google Scholar
  28. 28.
    Durant.I, Clevenbergh F, Halton F, et al.: Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195–2199.PubMedCrossRefGoogle Scholar
  29. 29.
    Baxter JD, Mayers DL, Wentworth DN, et al.: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS. AIDS 2000; 14 (9): F83–93.PubMedCrossRefGoogle Scholar
  30. 30.
    Cingolani A, Antinori A, Rizzo MG, et al.: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16: 369–379.PubMedCrossRefGoogle Scholar
  31. 31.
    Tural C, Ruiz L, Holtzer C, et al.: Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209–218.PubMedCrossRefGoogle Scholar
  32. 32.
    Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM; VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579–88PubMedCrossRefGoogle Scholar
  33. 33.
    Meynard JL, Vray M, Morand-Joubert L, et al.: Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Therapy 2000;5 suppl 3: 67–68.Google Scholar
  34. 34.
    The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance. AIDS 2001; 15: 309–320.CrossRefGoogle Scholar
  35. 35.
    Carpenter CC, Cooper DA, Fischi MA, et al.: Antiretroviral therapy in adults: updated recommendations ofthe International AIDS Society-USA Panel. JAMA 2000; 283: 381–390.PubMedCrossRefGoogle Scholar
  36. 36.
    Duwe S, Brunn M, Altmann D, et al.: Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 2001; 26: 266–273.PubMedCrossRefGoogle Scholar
  37. 37.
    Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708–712.PubMedCrossRefGoogle Scholar
  38. 38.
    Burger DM, Hoetelmans RMW, Mulder JW, et al.: Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy. 12th WorldAIDS Conference, Geneva, June 28-July 3, 1998: Abstr. 828Google Scholar
  39. 39.
    Acosta EP. The promise of therapeutic drug monitoring in HIV infection. August 1999. (http: //www. me d s c ap e.com/medsc ape/ HIV/journal/l999/v05.n04/mha0803/ mha0803. aco s/mha0803 acos-01. html) (See NAPS document no. 05584 for 5 pages, c/o Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.)Google Scholar
  40. 40.
    PiscitelIi SC. The limited value oftherapeutic drug monitoring in HIV infection. August 1999. (http://www.medscape.com/medscape/ HIV/journal/1999/v05.n04/mha0803/ mha0803.pisc/mha0803.pisc-01.html.) (See NAPS document no. 05584 for pages, do Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.)Google Scholar
  41. 41.
    Niehues T, Wintergerst U, Funk M, Notheis G et al.: Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern. Monatsschr Kinderheilkd 2001; 149: 1372–82.CrossRefGoogle Scholar
  42. 42.
    Deutsch-Österreichische Empfehlungen zur HIV-Therapie in der Schwangerschaft. Aktualisierung Mai 2001. http://www.rki.de/INFEKT/AIDS_STD/ BR_LINIE/BR_LINIE.HTMGoogle Scholar
  43. 43.
    Postexpositionelle Prophylaxe nach HIV-Exposition. Deutsch-Österreichische Empfehlungen. Aktualisierung Mai 2002. http://www.rki.de/INFEKT/AIDS_STD/ EXPO/HIV.HTMGoogle Scholar
  44. Boehm MF, Zhang L, Zhi L, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995; 38: 3146–3155PubMedCrossRefGoogle Scholar
  45. Chambon P. The molecular and genetic dissection of the retinoid signalling pathway. Rec Prog Horm Res 1995; 50: 317–332PubMedGoogle Scholar
  46. Drug Information for the Health Care Professional, USP DI (2002, 22nd Edition, Micromedex-Thompson Healthcare): pp 639–643Google Scholar
  47. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456–2471PubMedGoogle Scholar
  48. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15: 790–795PubMedGoogle Scholar
  49. Mukherjee R, Davies PJA, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407–410PubMedCrossRefGoogle Scholar
  50. Petkovich M, Brand NJ, KrustA, Chambon P. A human retinoic receptor which belongs to the family of nuclear receptors. Nature 1987; 330: 444–448PubMedCrossRefGoogle Scholar
  51. Rizvi NA, Marshall JL, Dahut W, et al. A phase I study of LGD 1069 in adults with advanced cancer. Clin Can Res 1999; 5: 1658–1664Google Scholar
  52. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Eng J Med 1999; 340: 1075–1079CrossRefGoogle Scholar
  53. Zackheim HS. Treatment of cutaneous T cell lymphoma with retinoids. Dermatologic Therapy 1998; 13: 207–215Google Scholar
  54. Althaus IW, Chou JJ, Gonzales AJ, et al. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol 1994; 47: 2017–28PubMedCrossRefGoogle Scholar
  55. Dueweke TJ, Poppe SM, Romero DL et al. U-90153S, a potent inhibitor of human deficiency virus type 1 replication. Antimicrob Agents Chemother 1993; 37: 1127–31PubMedCrossRefGoogle Scholar
  56. Freimuth WW. Delavirdinemesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. In: Mills J et al. (Eds) Antiviral Chemotherapy 4, Plenum Press, New York 1996, pp 279–289CrossRefGoogle Scholar
  57. Lacy CF, Armstrong LL, Goldman MP, Lance LL (Eds) The Drug Information Pocket 2002–2003, Lexi-Comp, Inc —AphA, p. 324Google Scholar
  58. Romero DL. Delavirdine mesylate–antiviral HIV-1 reverse transcriptase inhibitor. Drugs of the Future 1994; 19 (3): 238–242Google Scholar
  59. Scott LJ, Perry CM. Delavirdine: a review of its use in HIV infection. Drugs 2000; 60: 1411–1444PubMedCrossRefGoogle Scholar
  60. Drug tnformationfor the Health CareProfessional, USP DI (2002, 22nd Edition, Micromedex-Thompson Healthcare): pp 2649–2652Google Scholar
  61. Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996; 51: 846–864PubMedCrossRefGoogle Scholar
  62. Lin PP Samanta H, Rose RE, etal. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170: 1157–1164CrossRefGoogle Scholar
  63. Murray HW, Squires KE, Weiss Wet al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis 1995; 171 (Suppl 2): S123–130PubMedCrossRefGoogle Scholar
  64. Petersen EA, Ramirez Ronda CH, Hardy WD et al. Dose related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995; 171 (Suppl2): S131 - S139PubMedCrossRefGoogle Scholar
  65. Rana KZ, Dudley MN. Clinical pharmacokinetics of stavudine Clin Pharmacokinet 1997; 33: 276–284CrossRefGoogle Scholar
  66. Richman D, Staszewski S. HIV drug resistence and its implications for antiretroviral treatment strategies. International Medical Press Ltd (2“a Edition), London, Atlanta, 2000:Google Scholar
  67. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995; 171 (Suppl 2): S113 - S117PubMedCrossRefGoogle Scholar
  68. Broder S. Pharmacodynamics of2,3’-dideoxycytidine: an inhibitor ofhuman immunodeficiency virus.AmJMed 1990; 88 (Suppl 5B): 2S - 7SGoogle Scholar
  69. Collier AC, Coombs RW, Schoenfeld DA, et al. Extended treatment with saquinavir (SAQ), zidovudine (ZDV), and zalcitabine (ddC) vs SAQ and ZDV vs ddC and ZDV. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 1995, Abstract 1173Google Scholar
  70. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283–291CrossRefGoogle Scholar
  71. Devineni D, Gallo JM. Zalcitabine: clinical pharmacokinetics and efficacy. Clin Pharmacokinet 1995; 28: 351–360PubMedCrossRefGoogle Scholar
  72. Drug Information for the Health Care Professional, USP DI (2002, 22nd Edition, Micromedex-Thompson Healthcare): pp 2963–2966Google Scholar
  73. Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who receivedprevious zidovudine therapy. Ann Intern Med 1993; 118: 762–769PubMedCrossRefGoogle Scholar
  74. Jeffries DJ. The antiviral activityofdideoxycytidine. J Antimicrob Chemother 1989; 23 (Suppl A): 29–34PubMedCrossRefGoogle Scholar
  75. Meng T-C, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase VII study. Ann Intern Med 1992; 116: 13–20PubMedCrossRefGoogle Scholar
  76. Richman D, Staszewski S. HIV drug resistence and its implications for antiretroviral treatment strategies. International Medical Press Ltd ( 2nd Edition ), London, Atlanta, 2000: p. 20–21Google Scholar
  77. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection ofhuman immunodeficiency virus type 1 resistant to 3 ’ -thiacytidine inhibitors due to a mutation in the YMDDregionofreversetranscriptase. Proc Natl Acad Sci USA 1993; 90: 5653–5656PubMedCrossRefGoogle Scholar
  78. Whittington R. Brogden RN. Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 1992; 44: 656–683PubMedCrossRefGoogle Scholar
  79. Yarchoan R, Perno CF, Thomas RK et al. Phase I studies of2’,3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT) Lancet 1988; 1: 76–81Google Scholar
  80. Alkhatib, G. et al.: CC-CKR5: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955–1958 (1996).PubMedCrossRefGoogle Scholar
  81. Amara, A. et al.: HIV coreceptor downregulation as antiviral principle: SDF-la-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV-replication. Journal of Experimental Medicine 186 (1), 139–146 (1997).PubMedCrossRefGoogle Scholar
  82. Anderson, R.M. et al.: The Spread of HIV-1 in Africa: Sexual Contact Patterns and the Predicted Demographic Impact of AIDS. Nature 352, 581–588 (1991).PubMedCrossRefGoogle Scholar
  83. Carr, A. et al.: Pathogenesis of HIV-1-Protease Inhibitor-associated peripheral Lipodystrophy, Hyperlipidaemia, and Insulin Resistance. The Lancet 351 (9119), 1881–1883 (1998)CrossRefGoogle Scholar
  84. Chantapong, W. et al.: Determination of HIV-1 Subtypes in Injecting Drug Users in Bangkog, Thailand Using Peptide Binding Enzyme Immunoassay and The Heteroduplex Mobility Assay: Evidence of Increasing Prevalence of HIV-1 Subtype E. AIDS 9, 843–849 (1995).CrossRefGoogle Scholar
  85. Dietrich, U. et al.: A Highly Divergent HIV-2Related Isolate. Nature 11, 1155–1156 (1989).Google Scholar
  86. Dietrich, U. et al.: HIV-1 Strains from India are Highly Divergent from Prototypic African and US/European Strains, but are Linked to a SouthAfrican Isolate. AIDS 7, 23–27 (1993).PubMedCrossRefGoogle Scholar
  87. Eigen, M.: Viral Quasispecies. Scientific American 269 (1), 42–49 (1993).PubMedCrossRefGoogle Scholar
  88. Feng, Y. et al.: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane domain, G-protein coupled receptor. Science 272, 872–877 (1996).PubMedCrossRefGoogle Scholar
  89. Gao, F. etal.: Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436–441 (1999).PubMedCrossRefGoogle Scholar
  90. Goulder, P.J.R. and Walker, B.D.: HIV-1 Super-infection–A Word of Caution. New England Journal of Medicine 347 (10), 756–758 (2002).PubMedCrossRefGoogle Scholar
  91. Grez, M. etal.: Genetic analysis of HIV-1/HIV-2 mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. Journal of Virology, 2161–2168 (1994).Google Scholar
  92. Hirsch, M.S. and Curran, J.: Human Immunodeficiency Viruses. Biology and Medical Aspects in Virology edited by Fields, B.N. et al., 1545–1571 (1990).Google Scholar
  93. Levy, J.A.: HIV and The Pathogenesis ofAIDS. 2nd ed. Washington, D.C.: ASM Press, c1998, ISBN: 1–55581–122–1 (1998).Google Scholar
  94. Liu, R. et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multi-exposed individuals to HIV-1 infection. Cell 86, 367–377 (1996).PubMedCrossRefGoogle Scholar
  95. Mori, K. et al.: Suppression of acute viremia by short term postexposure prophylaxix of SHIV-RT infected monkeys with a novel RT inhibitor (GW420867) allows for development of potent antiviral immune responses. Resulting in efficient containment of infection. Journal of Virology 74, 5747–5753 (2000).PubMedCrossRefGoogle Scholar
  96. Mosca, J.D. et al.: Herpes simplex virus type 1 can reactivate transcription of latent human immunodeficiency virus. Nature 325, 67–70 (1987).PubMedCrossRefGoogle Scholar
  97. Oxenius, A. et al.: Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8’ and CD4’ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 97 (7) 3382–3387 (2000).PubMedCrossRefGoogle Scholar
  98. Pan, L. et al.: Detection of lasma Viremia in Human Immunodeficiency Virus.Infected Individuals at All Clinical Stages. Journal of Clinical Microbiology 31, 283–288 (1993).PubMedGoogle Scholar
  99. Pedersen C. et al.: The Effect of Treatment with Zidovudine +/- Acyclovir on HIV p24 Antigènaemia in Patients with AIDS or AIDS Related Complex. AIDS 6, 821–825 (1992).PubMedCrossRefGoogle Scholar
  100. Perelson, A.S. et al.: HIV-1 dynamics in vivo: Clearance rate, infected cell lifespan, and viral generation time. Science 271, 15821586 (1996).Google Scholar
  101. Rosenberg, E.S. etal.: Vigorous HIV-1-specific CD4+T cell responses associated with control of viremia. Science 278, 1447–1450 (1997).PubMedCrossRefGoogle Scholar
  102. Rübsamen-Waigmann, H. et al.: Reversal of HIV-Phenotype to Fulminat Replication on Macrophages in Perinatal Transmission. The Lancet 11, 1155–1156 (1989).CrossRefGoogle Scholar
  103. Rübsamen-Waigmann, H. and Dietrich, U.: Die Ahnen desAIDS-Virus. Bild der Wissenschaft 3, 92–96 (1991).Google Scholar
  104. Rübsamen-Waigmann, H. and Maniar, J.K.: HIV-2 Detected in India. The Microbiologist 2 (1), 4 (1991).Google Scholar
  105. Rübsamen-Waigmann, H.: Spread of HIV-2 in India. The Lancet 337 (3), 550–551 (1991).CrossRefGoogle Scholar
  106. Rübsamen-Waigmann, H. et al.: Markers for HIV-Disease Progression in Untreated Patients and Patients Receiving AZT: Evaluation of Viral Activity, AZT, Resistance, Serum Cholesterol b2-Microglobulin, CD4’ Cell Counts, and HIV-Antigen. Infection 19, 219222 (1991).Google Scholar
  107. Rübsamen-Waigmann, H. et al.: High Proportion of HIV-2 and HIV-1/-2 Double-reactive Sera in Two Indian States, Maharashtra and Goa: First Appearance of an HIV-2 Epidemic along with an HIV-1 Epidemic Outside of Africa. Zentralbl. f. Bakteriologie, Mikrobiologie und Hygiene 280, 398–402 (1994).Google Scholar
  108. Rübsamen-Waigmann, H. et al.: HIV-Infektion durch Gerinnungspräparate bei operiertem Patienten. Munch. med. Wschr., 136 (1994).Google Scholar
  109. Rübsamen-Waigmann, H. et al.: Second Generation Non-Nucleosidic Reverse Transcrip-tase Inhibitor HBY 097 and HIV-1 Viral Load. Research Letters Lancet 394, 1517 (1997).CrossRefGoogle Scholar
  110. Rübsamen-Waigmann, H.: Neue Konzepte zur Behandlung von AIDS und der HIV-Infektion. Spektrum der Wissenschaft. Dossier: Seuchen, 94–99 (1997).Google Scholar
  111. Rübsamen-Waigmann, H. et al.: Spread of HIV-2 in India. The Lancet 337 (3), 550–551 (1991).CrossRefGoogle Scholar
  112. Vesanen, M. et al.: Human Immunodeficiency Virus Type 1 mRNA Splicing Pattern in Infected Persons is Determined by The Proportion of Newly Infected Cells. Virology Vol. 236, 104–109 (1997).PubMedCrossRefGoogle Scholar
  113. Von Briesen, H. et al.: Isolation Frequency and Growth Properties of HIV-Variants: Multiple Simultaneous Variants in a Patient Demonstrated by Molecular Cloning. J. Med. Virol. 23, 51–66 (1987).CrossRefGoogle Scholar
  114. Von Briesen, H. et al.: Systematic Classification of HIV Biological Subtypes on Lymphocytes and Monocytes/Macrophages. Virology 178, 597–602 (1990).CrossRefGoogle Scholar
  115. Von Briesen, H. et al.: Infection of Monocytes/ Macrophages by HIV in Vitro. Res. Virol. 141, 251–257 (1990).CrossRefGoogle Scholar
  116. Dalichau G.: Gesundheitstrukturgesetz,Kommentar, Loseblattsammlung in 3 Bänden, Verlag RS Schulz GmbH, StarnbergGoogle Scholar
  117. Dalichau G, Grüner B, Müller-Alten L.: Pflegeversicherung Sozialgesetzbuch (SGB) Elftes Buch (XI) Kommentar sowie Bundes-, Europa-und Landesrecht Losteblattsammlung in 3 Bänden, Verlag RS Schulz GmbH, StarnbergGoogle Scholar
  118. Dalichau G., Grüner B.: Gesetzliche Krankenversicherung, Sozialgesetzbuch (SGB) Fünftes Buch (V) Kommentar, Loseblattsammlung in 3 Bänden, Verlag RS Schulz GmbH, StarnbergGoogle Scholar
  119. Exner-Freisfeld H: Soziale Absicherung bei HIV undAIDS, 2. aktualisierte und ergänzte Auflage, VAS Verlag fir akademische Schriften Frankfurt, 2001Google Scholar
  120. Exner-Freisfeld H.: Informationen zu AIDS in der Arbeitswelt, AIDS-Aufklärung e.V. Frankfurt a. Main 2. Auflage erscheint 2004Google Scholar
  121. Fritze E.: Die ärztliche Begutachtung 6. Auf- lage, Steinkopff-Verlag Darmstadt 2001Google Scholar
  122. Gostomzyk JG.: Angewandte Sozialmedizin, Handbuch für Weiterbildung und Praxis Grundwerk 2000, Landsberg/Lech: ecomedGoogle Scholar
  123. Grigoleit H., Schliehe F., Wenig M.: Handbuch Rehabilitation und Vorsorge Loseblattwerk Asgard Verlag Dr. Werner Hippe GmbH; Sankt AugustinGoogle Scholar
  124. Grüner B., Dalichau G.: Gesetzliche Rentenversicherung, Sozialgesetzbuch (SGB) Sechstes Buch (VI), Kommentar, Loseblattwerk in 3 Bänden, Verlag RS Schulz GmbH, StarnbergGoogle Scholar
  125. Jarke J.: AIDS amArbeitsplatz: Berufskrankheit HIV/AIDS in AIDS Herausforderungen für Forschung, Behandlung und das Leben mit HIV AIDS-Monographien, Band 8 2000 verlag moderne industrie-mi, Landsberg/Lech 433–435Google Scholar
  126. Jürgens A., Niermann T: Handbuch der Pflegeeinrichtungen in 2 Bänden Verlag RS Schulz GmbH, StarnbergGoogle Scholar
  127. Knittel SGB IX-Rehabilitation und Teilhabe Behinderter Menschen Kommentar und Rechtssammlung in 2 Bänden Verlag RS Schulz GmbH, StarnbergGoogle Scholar
  128. Kruse J., Reinhard HJ.: WinklerJBundessozialhilfegesetz ( BSHG) mitAsylbewerberleistungsgesetz Verlag C.H. Beck München 2002Google Scholar
  129. Leitfaden der Sozialhilfe von A-Z. Ausgabe 2002/2004 AG TuWas, DVS Frankfurt am Main 2002Google Scholar
  130. VDR Sozialmedizinische Begutachtung in der gesetzlichen Rentenversicherung, H. Exner-Freisfeld, S.375ff »HIV-Infektion und AIDS-Erkrankung« Gustav Fischer Verlag 1995Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • E. B. Helm
  • G. Just-Nübling
  • C. Jacobowski
  • H. Knechten
  • A. Goetzenich
  • K. Bröker
  • B. Knupp
  • P. Gute
  • J. Gölz
  • S. Nzimegne-Gölz

There are no affiliations available

Personalised recommendations